Hospital

Broad and successful implementation of technologies in complex health systems presents challenges, but is essential.

The partnership to deliver HIV medications will reduce transportation and access barriers for patients, especially in underserved communities.

Due to the success of mRNA technology with COVID-19, there has been a significant increase in research looking into utilizing mRNA technology, and more specifically, how it can help to advance vaccine development.

The 10 mL ready-to-administer pre-filled syringe in the first FDA-approved pre-filled syringe in this dosing size.

The inaugural Oncology Pharmacists Connect is directed toward pharmacists practicing in oncology in multiple practice environments.

Nivolumab met its primary endpoint of recurrence-free survival, reducing the risk of recurrence or death by 58% versus placebo in patients with completely resected stage 2B or 2C melanoma.

Pembrolizumab showed statistically significant improvement in the event-free survival of patients with resectable stage 2 or 3 non-small cell lung cancer.

Bruce Berger, PhD, president of Berger Consulting LLC, discusses how pharmacists should best use motivational interviewing for patients.

Pharmacy Times® commits to incorporating DEI concepts into our coverage and focusing on social determinants of health (SDOH).

The FDA set a Prescription Drug User Fee Act for May 2023 for Pfizer’s respiratory syncytial virus bivalent vaccine candidate.

Friedreich’s ataxia is a rare neuromuscular disease that affects approximately 5000 patients in the United States.

The effectiveness of 2 doses against Omicron infection was highest when the second dose was given in the third trimester of pregnancy compared with the first or second trimesters.

Clinical guidelines suggest screening for cardiovascular risk factors post-partum in women, however, these recommendations are not closely followed, a new study suggests.

The company is also launching Rezvoglar, a biosimilar to Lantus injection, for $92 per 5-pack of KwikPens.

Sarilumab is a fully human monoclonal antibody indicated for patients with polymyalgia rheumatica who had an inadequate response to corticosteroids or are unable to tolerate corticosteroid taper.

Study results indicates that the injectable antiretroviral therapy can benefit patients who are historically underserved and may face treatment barriers, including those with mental illness.

The set of principles seeks to improve publication patterns to show the value of the pharmacist and how journals can strengthen pharmacy practice as a scientific discipline.

Metformin may accelerate paclitaxel’s actions on cell replication in endometrial cancer.

Companies seek FDA approval for individuals aged 12 years and older to receive vaccinations for their primary series.

Many laws also allow physicians to decide which information they disclose to guardians or fail to address inadvertent breaches of confidentiality through insurance billing and claims.

Patients who had relapsed or treatment-resistant cancer at baseline, or those who had more severe acute COVID-19 infections, were less likely to develop long COVID-19.

AI models can predict pharmacy foot traffic and peak service times, and even analyze patient histories to single out who picks up their prescriptions on time.

Phase 3 trial results indicate efficacy against respiratory syncytial virus-lower respiratory tract disease in individuals aged 60 years and older.

Data show continued objective response rate, overall survival, and progression-free survival benefits of nivolumab plus cabozantinib in the treatment of advanced renal cell carcinoma.

Evaluating tasks, such as appropriate site of care and plan benefits, frees up time for pharmacists.

Virologic suppression was similar between the long-acting and once-daily treatments for HIV, but participants were more satisfied with the former.

Lenacapavir, combined with broadly neutralizing HIV antibodies, found effective at viral suppression in patients with HIV.

Altuviiio [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl; Sanofi] is high-sustained factor VIII replacement therapy indicated for routine prophylaxis and on-demand treatment to control bleeding episodes and for perioperative management in adults and children with hemophilia A.